Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanistic Trial of Temtokibart vs Dupilumab in Atopic Dermatitis
NCT05470114Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- May 2022
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of temtokibart in atopic dermatitis (AD) (2 arms), sponsored by LEO Pharma. Primary endpoint: Change in Gene Expression Typically Associated With Atopic Dermatitis in Lesional Skin Biopsies at 4 weeks. Started May 2022; status: completed.
02
Drugs
temtokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05470114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470114.